[Fibrinogen and factor VII levels in patients under estrogen-progestin therapy].
During a 3 month period the Authors have evaluated the possible modification of some coagulation parameters which can be of relevance for thrombophilic state. Fibrinogen and factor VII were measured and following 3 months of oestro-progestinic treatment in 11 women in good general health and without known controindications to contraceptive treatment. No significant difference in some levels of fibrinogen and factor VII were found. We conclude that in the short term fibrinogen and factor VII are not significantly altered but a longer period of follow up is indicated in order to estimate the risk of cardiovascular accidents.
Tani
M
M
Laboratorio Analisi Chimico-Cliniche e Microbiologia, Ospedale Civile, Gavardo, Brescia.
Bossini
S
S
Maffetti
G
G
D001778:Blood Coagulation Disorders / Q000139:chemically induced* / Q000517:prevention & control; D001780:Blood Coagulation Tests; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control; D004967:Estrogens / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005167:Factor VII / Q000032:analysis*; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D006801:Humans; D011372:Progestins / Q000008:administration & dosage* / Q000493:pharmacokinetics
D004967:Estrogens; D011372:Progestins; D005167:Factor VII; D005340:Fibrinogen
Dosaggio del fibrinogeno e del fattore VII in pazienti che assumono terapia estroprogestinica.